Trial · NCT03839355
Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
NCT03839355, Phase 3, Terminated, Mayo Clinic; results first posted 2021-03-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation. Trials, record NCT03839355. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03839355
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
- NCT number
- NCT03839355
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 34 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Atrial Fibrillation
- Interventions
- Apixaban, Warfarin
- First posted
- 2019-02-15
- Last updated
- 2021-03-16
- Results first posted
- 2021-03-16
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Standardized Neurocognitive Function Score | Baseline, Year 1, Year 2 | Assess the change in cognitive function using standardized neurocognitive assessment. |
| Primary | MRI Evidence of Silent Cerebral Infarct | Baseline, Year 2 | Magnetic Resonance Imagining of the brain to assess the development of new silent cerebral infarcts. |
| Primary | MRI Evidence of New Cerebral Micro-bleeds | Baseline, Year 2 | Magnetic Resonance Imagining of the brain to assess the development of new cerebral micro-bleeds |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Standardized Neurocognitive Function Score | Baseline, Year 1, Year 2 | Study terminated due to slower than anticipated enrollment. Data was not collected or analyzed. | ||
| PRIMARY | MRI Evidence of Silent Cerebral Infarct | Baseline, Year 2 | Study terminated due to slower than anticipated enrollment. Data was not collected or analyzed. | ||
| PRIMARY | MRI Evidence of New Cerebral Micro-bleeds | Baseline, Year 2 | Study terminated due to slower than anticipated enrollment. Data was not collected or analyzed. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Eliquis | 18 | |
| Overall Study | STARTED | Warfarin | 16 | |
| Overall Study | COMPLETED | Eliquis | 17 | |
| Overall Study | COMPLETED | Warfarin | 16 | |
| Overall Study | NOT COMPLETED | Eliquis | 1 | |
| Overall Study | NOT COMPLETED | Warfarin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Eliquis | 0 | 18 |
| Total, all-cause mortality | Warfarin | 0 | 16 |
| Total, other adverse events | Eliquis | 0 | 18 |
| Total, other adverse events | Warfarin | 0 | 16 |
| Total, serious adverse events | Eliquis | 0 | 18 |
| Total, serious adverse events | Warfarin | 0 | 16 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Eliquis vs Warfarin: deaths from any cause | Trial comparisons |
| Eliquis vs Warfarin: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03839355
GET https://conductscience.org/api/trials/v1/NCT03839355/registered